Coproduction of novel 16S rRNA methylase RmtD and metallo-beta-lactamase SPM-1 in a panresistant pseudomonas aeruginosa isolate from Brazil by Doi, Yohei et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Mar. 2007, p. 852–856 Vol. 51, No. 3
0066-4804/07/$08.000 doi:10.1128/AAC.01345-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.
Coproduction of Novel 16S rRNA Methylase RmtD and
Metallo--Lactamase SPM-1 in a Panresistant
Pseudomonas aeruginosa Isolate from Brazil
Yohei Doi,1* Doroti de Oliveira Garcia,2 Jennifer Adams,1 and David L. Paterson1
Division of Infectious Diseases, University of Pittsburgh Medical Center, Pittsburgh,
Pennsylvania 15213,1 and Instituto Adolfo Lutz, Sa˜o Paulo, Brazil2
Received 26 October 2006/Returned for modification 29 November 2006/Accepted 30 November 2006
Serious infections with Pseudomonas aeruginosa are frequently treated with the combination of a -lactam
antimicrobial and an aminoglycoside. P. aeruginosa strain PA0905 was isolated in 2005 from an inpatient in
Brazil. It showed a panresistant phenotype that included resistance to -lactams, aminoglycosides, and
fluoroquinolones. The -lactam resistance was conferred by the production of the metallo--lactamase SPM-1.
No inhibitory zone was observed when a disk diffusion test was performed with the semisynthetic aminogly-
coside arbekacin, raising suspicion of 16S rRNA methylase production. A cloning experiment subsequently
revealed the presence of a novel 16S rRNA methylase, RmtD, which accounted for the high-level resistance to
all 4,6-disubstituted deoxystreptamine aminoglycosides, such as amikacin, tobramycin, and gentamicin. RmtD
shared a moderate degree of identity with RmtA, another 16S rRNA methylase that was initially reported to
occur in P. aeruginosa in Japan in 2003. This is the first identification of aminoglycoside resistance mediated
by a 16S rRNA methylase in South America. This is also the first report to document coproduction of a
metallo--lactamase and a 16S rRNA methylase, a combination that would severely compromise therapeutic
options for the infected patients.
Serious infections with Pseudomonas aeruginosa are associ-
ated with substantial mortality (13). Although the merits of
combination antimicrobial therapy with use of a -lactam and
an aminoglycoside have been debated, many guidelines do
recommended such combinations (1). Coproduction of potent
mechanisms of resistance to both -lactams and aminoglyco-
sides may therefore have considerable clinical impact.
A wide range of -lactamases are known to be produced by
P. aeruginosa, including metallo--lactamases, which may com-
promise all -lactam antimicrobials except aztreonam (3). Pro-
duction of a 16S rRNA methylase has recently emerged as a
mechanism of high-level resistance to all 4,6-disubstituted de-
oxystreptamine aminoglycosides, such as amikacin, tobramy-
cin, and gentamicin (8, 24). Therefore, coproduction of a
metallo--lactamase and a 16S rRNA methylase may result in
an extremely significant antimicrobial resistance profile.
Four 16S rRNA methyltransferases have been identified
thus far. RmtA was reported to occur in Pseudomonas aerugi-
nosa clinical isolates in Japan (24, 26), whereas ArmA and
RmtB have been identified among various species belonging to
the Enterobacteriaceae in Europe and East Asia (7, 8, 11, 24,
25). In addition, RmtC was most recently found from Proteus
mirabilis in Japan (22). All of the responsible genes have been
found in association with transposons or transposon-like
elements (5, 9, 22, 23). Functionality of these transposons
have been demonstrated for ArmA and RmtC, suggesting
that transposase-mediated recombination events are likely
responsible for the acquisition and dissemination of these
genes (8, 21).
P. aeruginosa PA0905 was isolated from an inpatient at a
hospital in Brazil in 2005. The strain showed panresistance,
including high-level resistance to carbapenems and multiple
aminoglycosides, including amikacin, tobramycin, and genta-
micin (14). The strain did not form an inhibitory zone around
a Kirby Bauer disk impregnated with 30 g of arbekacin, a
semisynthetic aminoglycoside. Demonstration of high-level re-
sistance to arbekacin in gram-negative pathogens has been
reported to be suggestive of aminoglycoside resistance medi-
ated by production of 16S rRNA methylases (5). Cloning ex-
periments were therefore conducted to identify the aminogly-
coside resistance determinant in P. aeruginosa PA0905.
MATERIALS AND METHODS
Bacterial strains and plasmids. P. aeruginosa PA0905 was isolated in 2005
from the urine of an inpatient at a hospital in the city of Sorocaba, approximately
80 km west of Sa˜o Paulo, Brazil. P. aeruginosa PA01 and Escherichia coli XL1-
Blue were used as the hosts in transformation experiments. pBC SK() and
pBluescript II SK() (Stratagene, La Jolla, CA) were used as the cloning vec-
tors.
Antimicrobial susceptibility testing. Aminoglycosides were obtained from
Sigma (St. Louis, MO), except for arbekacin, which was provided by Meiji Seika
Kaisha Ltd. (Tokyo, Japan). The MICs of aminoglycosides were determined by
use of the agar dilution method in accordance with the recommendations from
the Clinical and Laboratory Standards Institute (CLSI) (4), using E. coli ATCC
25922 as the control strain. The MICs of -lactams, ciprofloxacin, and colistin for
P. aeruginosa PA0905 were determined by Etest (AB Biodisk, Solna, Sweden).
Kirby Bauer disks containing 30 g of arbekacin were obtained from Eiken
Kagaku Co., Ltd. (Tokyo, Japan).
Detection of metallo--lactamase production. Etest MBL (AB Biodisk) was
used to screen for metallo--lactamase production. PCR for detection of blaSPM
was conducted as previously described (6).
Transfer of aminoglycoside resistance genes. Plasmids of P. aeruginosa
PA0905 were extracted by use of both the Wizard Plus Minipreps DNA purifi-
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cation system (Promega, Madison, WI) and the method described by Kado and
Liu (10). Electrocompetent E. coli XL1-Blue and P. aeruginosa PA01 were
transformed by the plasmids. Transformants were selected on Luria-Bertani
(LB) agar plates containing 10 and 50 g/ml of amikacin for E. coli XL1-Blue
and P. aeruginosa PA01, respectively.
Curing of plasmids. Curing experiments were conducted according to the
methods described by Trevors (20). Briefly, P. aeruginosa PA0905 was cultured
overnight in LB broth containing 128 g/ml of ethidium bromide, which was the
highest concentration with appreciable growth. The broth was then aliquoted
onto plain LB agar plates. The colonies were subsequently replicated on LB agar
plates with and without 50 g/ml of arbekacin to evaluate for loss of arbekacin
resistance.
Cloning of the aminoglycoside resistance gene. The genomic DNA of P.
aeruginosa PA0905 was prepared and digested with BamHI, and the resultant
fragments were ligated with plasmid vector pBC SK(). Electrocompetent E.
coli XL1-Blue was prepared and transformed with these plasmids. Transfor-
mants were selected on LB agar plates containing 30 g/ml of chloramphenicol
and 10 g/ml of amikacin. For use in MIC determination, the recombinant
plasmid obtained was partially digested with Sau3AI and ligated with pBluescript
II SK(). The transformants carrying the aminoglycoside resistance determinant
were selected out on LB agar plates containing 50 g/ml of ampicillin and 10
g/ml of amikacin.
Nucleotide sequence accession number. The nucleotide sequence containing
rmtD determined in this study appears in the EMBL/GenBank/DDBJ databases
under accession number DQ914960.
RESULTS
Aminoglycoside and carbapenem resistance of P. aeruginosa
PA0905. P. aeruginosa PA0905 showed a high level of resis-
tance to arbekacin, amikacin, tobramycin, and gentamicin (Ta-
ble 1). It was resistant to ceftazidime (MIC, 256 g/ml),
cefepime (256 g/ml), piperacillin-tazobactam (192 g/ml),
imipenem (32 g/ml), meropenem (32 g/ml), and cipro-
floxacin (32 g/ml) but was susceptible to aztreonam (8 g/
ml) and colistin (1.0 g/ml).
Detection of metallo--lactamase production. By Etest
MBL, the MIC of imipenem for P. aeruginosa PA0905 was
reduced by greater than eightfold in the presence of EDTA,
suggesting the presence of a metallo--lactamase. PCR for
blaSPM yielded an amplicon, which was confirmed to represent
blaSPM-1 upon sequencing.
Cloning and sequencing of aminoglycoside resistance gene.
When electrocompetent E. coli XL1-Blue cells were trans-
formed with recombinant plasmids consisting of a BamHI-
digested genomic library of P. aeruginosa PA0905 ligated with
pBC SK(), two colonies were obtained by selection with
amikacin and chloramphenicol. They possessed a recombinant
plasmid containing a 2.3-kb BamHI insert (pPA95B1), which
was then sequenced. The structure of the sequence is shown in
Fig. 1. The initial 0.5 kb of the sequence contained the 3 end
of an open reading frame. It showed 70% identity to part of the
putative tRNA ribosyltransferase located upstream of rmtA
(23). The next open reading frame predicted a protein with 247
amino acids and molecular mass of ca. 28 kDa. Its deduced
amino acid sequence showed moderate identity with those of
previously reported 16S rRNA methylases that confer high-
level resistance to 4,6-disubstituted deoxystreptamine amino-
glycosides in gram-negative pathogens. The open reading
frame was thus designated rmtD as a novel 16S rRNA meth-
TABLE 1. Results of antimicrobial susceptibility testing
Antimicrobial
agent
MIC (g/ml) for:
P. aeruginosa
PA0905
E. coli XL1-Blue
(pPA95S29)
E. coli XL1-Blue
pBluescript II SK()
Arbekacin 256 256 0.25
Amikacin 256 256 0.5
Tobramycin 256 64 0.06
Gentamicin 256 256 0.25
Apramycin 32 2.0 2.0
Neomycin 64 0.12 0.12
Streptomycin 128 1.0 0.5
FIG. 1. Schematic presentation of the genetic structure of the cloned regions containing rmtD. oriIS indicates the putative insertion site of
transposition and its sequence. The lower sequence represents the consensus sequence of oriIS for IS91-related transposons.
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ylase gene. The deduced amino acid sequence of the gene
product showed 42% identity with that of RmtB, followed by
40% with that of RmtA (Fig. 2). Its GC content was 59%,
similar to that of RmtA (55%) but somewhat lower than the
genomic content of P. aeruginosa (67%). The last 0.4 kb of the
sequenced region contained the 3 end of an open reading
frame downstream of rmtD. Its predicted amino acid sequence
shared approximately 80% identity with those of putative
transposases reported for the blaPSE-1-containing Tn2610 in E.
coli as well as ISCR5S, located upstream of blaOXA-45 in P.
aeruginosa (15, 17, 19). It also had moderate (54%) identity
with Orf513, which constitutes the common region down-
stream of sul1-type complex class 1 integrons (ISCR1) and is
assumed to encode a recombinase responsible for accumula-
tion of various antimicrobial resistance genes (17). A putative
insertion site of transposition (oriIS) was identified 224 bp
downstream of the 3 end of the putative transposase gene
(Fig. 1). The oriIS contained a sequence identical to that of
ISCR3, which consisted of 5-GCGTATAGGAAGTTCAAA
CGC-3 (18).
Transfer of aminoglycoside resistance and curing experi-
ments. No transformant with resistance to amikacin and pos-
itive for the presence of the rmtD gene by PCR was obtained,
despite repeated attempts. Curing experiments did not yield
arbekacin-susceptible isolates.
Antimicrobial susceptibilities. The MICs of various amino-
glycosides for the parental strain P. aeruginosa PA0905 and for
E. coli XL1-Blue harboring pPA95S29, a truncated derivative
of pPA95B1, are shown in Table 1. The results confirmed the
substantial role of rmtD in the high-level resistance of P. aerugi-
nosa PA0905 against 4,6-disubstituted deoxystreptamine ami-
noglycosides, including arbekacin, amikacin, tobramycin, and
gentamicin. It did not confer resistance to apramycin, neomy-
cin, or streptomycin, which are structurally different aminogly-
cosides. The latter finding suggested that other mechanisms,
especially aminoglycoside-modifying enzymes, may play a role
FIG. 2. Amino acid sequence of RmtD in comparison with those of known 16S rRNA methylases RmtA (GenBank accession number
AB083212), RmtB (AB103506), RmtC (AB194779), and ArmA (AY220558).
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in the resistance against these agents in the parental strain
PA0905.
DISCUSSION
The present study for the first time identified a clinical
isolate of P. aeruginosa that produced both a 16S rRNA
methylase and a metallo--lactamase. The antimicrobial ar-
mamentarium for infections caused by multidrug-resistant
or panresistant P. aeruginosa strains is extremely limited
(14). Antipseudomonal cephalosporins, such as ceftazidime
and cefepime; carbapenems, including imipenem and mero-
penem; and the antipseudomonal aminoglycosides tobramy-
cin and amikacin are among the few therapeutic options if
susceptibility is retained. Coproduction of a metallo--lac-
tamase and a 16S rRNA methylase confers high-level resis-
tance to all of the aforementioned agents. The emergence of
such isolates therefore further adds to the complexity of
treatment of infections caused by this species. Among all
available antipseudomonal antimicrobials tested, the isolate
remained susceptible only to aztreonam and colistin. Az-
treonam is a monobactam that is known to be stable against
the hydrolytic activity of metallo--lactamases (3). Aztreo-
nam-resistant isolates of P. aeruginosa that produce SPM-1
metallo--lactamase have been reported, however, implying
that these organisms are capable of acquiring additional
resistance mechanisms targeting aztreonam (27).
This is also the first report to document the emergence of
16S rRNA methylase-mediated aminoglycoside resistance in
either North or South America. This novel resistance mecha-
nism in gram-negative pathogens is increasingly recognized
worldwide since the initial reports in 2003. ArmA and RmtB
have been reported from many countries in Europe and East
Asia, often in association with CTX-M-type -lactamases,
whereas RmtA and RmtC are confined to Japan to date (8, 22,
24). However, it is possible that the prevalence of this resis-
tance mechanism is underestimated. This assumption may be
made due to the fact that clinical isolates are not always tested
for susceptibility to multiple aminoglycosides and, even so,
determinations of MICs higher than the breakpoints are not
performed routinely. The hallmark of resistance by production
of a 16S rRNA methylase is high-level resistance to multiple
4,6-disubstituted deoxystreptamine aminoglycosides. These
agents comprise practically all parenterally formulated amino-
glycosides in clinical use, and thus the presence of this resis-
tance mechanism may not easily be detected in current routine
susceptibility testing.
RmtD is the fifth 16S rRNA methylase identified in gram-
negative organisms and the second in P. aeruginosa (after
RmtA), adding to the growing family of aminoglycoside-resis-
tance 16S rRNA methylases (Fig. 3). Its structural gene was
identified in association with a putative transposase accompa-
nied by an intact insertion site of transposition. Although the
entire structure of the transposon carrying rmtD is yet to be
elucidated, this finding suggests that rmtD was possibly mobi-
lized to the genomic content of P. aeruginosa by a rolling-circle
transposition event mediated by a novel IS91-like CR element
(16, 18). These findings point to the possibility that rmtD, with
a lower GC content than that in the P. aeruginosa genome, may
have been acquired through recombination events from a
group of closely related bacterial species that are yet to be
identified.
Two cardinal sites of methylation are known among 16S
rRNA methylases produced by aminoglycoside-producing ac-
tinomycetes. Methylation of G1405 within the A site of 16S
rRNA is associated with a kanamycin-gentamicin resistance
phenotype, whereas that of A1408 is associated with a kana-
mycin-apramycin resistance phenotype (2). Though the site of
methylation in RmtD was not examined, the resistance pattern
that includes gentamicin but not apramycin is suggestive of the
residue G1405 being the substrate of the methylation event, as
was recently shown to be the case in ArmA (12).
Arbekacin served as a useful marker for screening the isolate
studied here as a potential 16S rRNA methylase producer, as
has been reported previously (5). Arbekacin is a semisynthetic
derivative of dibekacin and is stable against most aminoglycoside-
modifying enzymes. When gram-negative pathogens highly resis-
tant to both amikacin or tobramycin and gentamicin are encoun-
tered, testing for arbekacin resistance remains a simple and
effective method for screening for 16S rRNA methylase produc-
tion, as was demonstrated for this RmtD-producing organism,
which formed no inhibitory zone around an arbekacin-containing
disk. This two-step screening method may facilitate early detec-
tion of the presence of 16S rRNA methylase-mediated aminogly-
coside resistance.
In conclusion, we have reported a novel aminoglycoside
resistance 16S rRNA methylase, RmtD, in a panresistant P.
aeruginosa clinical isolate which coproduced the metallo--
lactamase SPM-1. Of the 16S rRNA methylases known to date,
RmtD and its genetic structure are phylogenetically close to
RmtA, both of which were identified in P. aeruginosa but in
geographically distant parts of the world. The use of arbekacin
as a screening tool with gram-negative pathogens resistant to
multiple aminoglycosides may enhance detection of this
emerging resistance mechanism and thus lead to early contain-
ment through timely implementation of infection control pro-
cedures.
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